Revelation Biosciences (REVB) Projected to Post Earnings on Friday

Revelation Biosciences (NASDAQ:REVB) is anticipated to announce its earnings results before the market opens on Friday, March 28th. Analysts expect the company to announce earnings of ($3.20) per share for the quarter.

Revelation Biosciences Trading Down 3.4 %

Revelation Biosciences stock opened at $2.88 on Wednesday. The firm has a market capitalization of $2.61 million, a P/E ratio of -0.01 and a beta of 0.17. Revelation Biosciences has a twelve month low of $2.36 and a twelve month high of $60.80. The stock’s fifty day simple moving average is $4.09 and its 200-day simple moving average is $8.74.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.